Opinion

Video

Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.

  1. In addition to cost, what factors influence coverage decisions for AD treatments?
  2. How do step-therapy protocols and prior authorization approval process influence the prescribing patterns of topical therapies (and progressing to systemic therapies) for AD among healthcare providers?
  3. What strategies can healthcare providers implement to streamline the PA approval process for topical AD therapies and reduce administrative burdens while still ensuring cost-effective care?
    1. Please discuss the burden providers face in terms of workload perspective, staffing constraints, etc, and what this means for patients
Related Videos
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
4 KOLs are featured in this series
Surbhi Sidana, MD, MBBS
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
1 KOL is featured in this series.
Screenshot of Susan Wescott, RPh, MBA
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo